DianaMarinaBrainardMD
Infectious Disease • Boston, MAVice President, Clinical Research at Gilead Sciences
Are you Dr. Brainard?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 64 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-9060Fax+1 617-726-5411
Summary
- Dr. Diana Brainard, MD is an infectious disease specialist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is a Vice President at Clinical Research at Gilead Sciences.
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2001 - 2004- Massachusetts General HospitalResidency, Internal Medicine, 1997 - 2000
Tulane University School of MedicineClass of 1997
Certifications & Licensure
MA State Medical License 1999 - 2012
Clinical Trials
- A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Start of enrollment: 2010 Aug 01
- A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment Start of enrollment: 2013 Mar 01
Publications & Presentations
PubMed
- 87 citationsCapsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.Sorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, Antonella Castagna, Gary J Richmond
The New England Journal of Medicine. 2022-05-12 - 13 citationsSwitching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.Debbie Hagins, Princy Kumar, Michael S. Saag, Anson K Wurapa, Indira Brar
Journal of Acquired Immune Deficiency Syndromes. 2021-09-01 - 61 citationsSwitching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.Paul E. Sax, Jürgen K. Rockstroh, Anne F Luetkemeyer, Yazdan Yazdanpanah, Douglas J. Ward
Clinical Infectious Diseases. 2021-07-15
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Join now to see all
Press Mentions
AlloVir to Present at the BofA Securities 2023 Health Care ConferenceMay 1st, 2023- AlloVir Announces Positive Results in Oral Presentation at EBMT 2023, Including Long-Term Mortality Data from Phase 2 Posoleucel Multiviral Prevention StudyApril 26th, 2023
- AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023January 9th, 2023
- Join now to see all
Grant Support
- The Effects Of HIV GP120 On CTL Migration And EfficacyNational Institute Of Allergy And Infectious Diseases2004–2006
